Please login to the form below

Not currently logged in
Email:
Password:

Lu AE58054

This page shows the latest Lu AE58054 news and features for those working in and with pharma, biotech and healthcare.

Lundbeck trial failure dashes hopes in Alzheimer's once again

Lundbeck trial failure dashes hopes in Alzheimer's once again

Idalopirdine (Lu AE58054) appeared to be safe and showed evidence of "weak efficacy" in the phase III STARSHINE study, which enrolled patients with mild to moderate Alzheimer's.

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    The first phase III study in patients with mild-to-moderate Alzheimer's disease will assess Lu AE58054 as an adjunct treatment to donepezil. ... The Lu AE58054 deal comes out of an already successful relationship between Lundbeck and Otsuka.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics